TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12452946
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose gum (900 mg CaCO3)
Study: 1932838
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (oophorectomy + tamoxifen) in pre-menopausal patients
Study: 29984691
Drug: 6-monthly PI
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly PI
Study: 8896777
Drug: Bright white
Normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white light (2500 lx) for 2 hours daily for 1 week
Study: 10418644
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propacetamol and tenoxicam
Study: 25385173
Drug: enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril and atorvastatin (ACEI)
Study: 16682738
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cisplatin and fluorouracil (reference arm in Western trials)
Study: 16682738
Drug: Single-agent fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-agent fluorouracil or S-1 (used in Japanese trials)
Study: 16191910
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health program
Study: 2961039
Drug: Components of
Normalized name: TRAVOPROST COMPONENT OF DUOTRAV
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Components of the combination therapy
Study: 18775429
Drug: Anti-Hp therapy
Normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Hp therapy alone (2-week anti-Hp therapy)
Study: 31096648
Drug: Sunflower seed
Normalized name: SUNFLOWER SEED
DrugBank: Sunflower seed (DB10907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower seed extract (500 mg/day)
Study: 29334275
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Cetrotide 0.25 mg) combined with cabergoline (0.5 mg a day for 8 days)
Study: 3556145
Drug: Tryptophan 250
Normalized name: tryptophan 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan 250 mg
Study: 15738750
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg modafinil
Study: 9028537
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (hGH) treatment
Study: 8503338
Drug: Flutamide 375
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 375 mg/day
Study: 26299751
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) group, 8 weeks upper limb training, same dosage as BAL group
Study: 2521297
Drug: Brequinar sodium
DrugBank: Brequinar (DB03523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brequinar sodium (various schedules: short-term IV infusion every 3 weeks, weekly, twice weekly, five times daily every 4 weeks)
Study: 8822590
Drug: 8 mmol
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mmol MgSO4 intravenous bolus over 15 min followed by 3 mmol MgSO4/h
Study: 17986038
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia with midazolam, ketamine, and propofol (MKP group)
Study: 24021291
Drug: Sodium ferric
Normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferric gluconate complex (SFGC) infused IV at 62.5 mg over 30 minutes (Study 2)
Study: 8905422
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) at 1 mg/kg per hour over 24 h
Study: 17012878
Drug: Menomune (PSV-4)
Normalized name: MENINGOCOCCAL POLY (MENOMUNE) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menomune (PSV-4) vaccine
Study: 11158752
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg once daily for 7 days
Study: 2658392
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at night
Study: 6737208
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise treatment
Study: 28709817
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line treatment
Study: 2132289
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (300 mg bid)
Study: 29630018
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics
Study: 18989992
Drug: Nebicapone 50
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone 50 mg
Study: 18989992
Drug: Nebicapone 100
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone 100 mg
Study: 18989992
Drug: Nebicapone 200
Normalized name: Nebicapone
DrugBank: Nebicapone (DB14849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebicapone 200 mg
Study: 26688732
Drug: Ciprofloxacin DPI
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin DPI 32.5 mg
Study: 8604260
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (25 to 50 microg/kg/min over 24 hours)
Study: 9280552
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel TX 11323 (A)
Study: 15919462
Drug: Daclizumab (DZB)
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab (DZB) treatment
Study: 8356584
Drug: CsA high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA high dose
Study: 18491582
Drug: Lisinopril monotherapy
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril monotherapy
Study: 17105798
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) - 150 mg of testosterone enanthate intramuscularly every 2 weeks for 6 months
Study: 12860942
Drug: Oxaliplatin at
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin at 130 mg/m2 every 3 weeks
Study: 1330470
Drug: Amantadine 100
Normalized name: amantadine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 100 mg/bid for 10.5 days
Study: 3901660
Drug: Commercial low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial low sodium glucose-electrolyte solution (sodium 35 mmol/l, glucose 3.5 milligrams)
Study: 20504306
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (15 microg HA/strain/0.5-ml dose) administered intramuscularly
Study: 24828092
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine
Study: 22906943
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine
Study: 10414910
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration (early vs delayed)
Study: 16235180
Drug: 7-valent conjugate
Normalized name: PNEUMOCOCCAL 7-VALENT CONJUGATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent conjugate pneumococcal vaccine (CPV); 2 doses, 4 weeks apart
Study: 20519807
Drug: Miglitol administered
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol administered just before a meal (50 mg)
Study: 22317952
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m(2) every 3 weeks (C)
Study: 22645323
Drug: Maintenance steroids
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance steroids
Study: 22121857
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment for 2 months
Study: 26529118
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg
Study: 22665264
Drug: Citalopram 10
Normalized name: citalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 10 mg
Study: 3467975
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg
Study: 18582395
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 300 mg/day
Study: 7225741
Drug: Chemotherapy (CMF)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CMF)
Study: 9504355
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg
Study: 23830392
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment
Study: 8117641
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 0.1% ophthalmic solution
Study: 27285466
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg, administered twice daily for 9 doses
Study: 1586733
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin
Study: 15190136
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of dexamethasone
Study: 3818148
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg
Study: 29139142
Drug: Levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium (10× the labeled starting dose)
Study: 28320484
Drug: Twice-daily intervention
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily intervention nutritional drink enriched with additional micronutrients, myo-inositol, and probiotics.
Study: 21042763
Drug: Early changes
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early changes in tumour markers during treatment
Study: 19213350
Drug: Oral Medicated
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Medicated (OM) group
Study: 7594343
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg
Study: 8154016
Drug: Intramuscular sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular sulfadoxine-pyrimethamine
Study: 22274319
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with the same regimen as the IVCT arm followed by radical surgery (arm IACT)
Study: 27380034
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of treatment
Study: 7480568
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (14 days)
Study: 2403006
Drug: Changed to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changed to once-daily treatment at the same weekly dose (second year)
Study: 12946941
Drug: Duodenal lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal lipid infusion (1 kcal/min) with distal (rectal) distension (n = 8)
Study: 2892450
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg
Study: 15792395
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 500 microg via Diskus, twice daily
Study: 6162348
Drug: Lidocaine-prilocaine cream
Normalized name: lidocaine / prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine-prilocaine cream
Study: 10831008
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray (220 microg)
Study: 28778464
Drug: GET 73
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GET 73 single ascending doses (10, 30, 100, 300, 450, 600 mg)
Study: 25913479
Drug: AML-BFM 98
Normalized name: AML-2-23
DrugBank: AML-2-23 (DB17433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AML-BFM 98 treatment protocol
Study: 28860012
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of rocuronium (bolus-NMB-group)
Study: 18705632
Drug: Metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 0.75% cream
Study: 31168802
Drug: Subcutaneous crenezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous crenezumab (300mg) every 2 weeks
Study: 24002929
Drug: Landiolol hydrochloride
Normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol hydrochloride (low dose): 0.125 mg/kg/min (1 min) loading followed by 0.02 mg/kg/min (20 min) continuous infusion
Study: 22842835
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (PRT) for three months, twice a week, focusing on lower limb muscles
Study: 20542898
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 mg, 2-4 hours prior to surgery)
Study: 20542898
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 mg, 6-8 hours prior to surgery)
Study: 17269558
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil concentrate (6 g/d, 4.4 g of LCn‐3PUFA)
Study: 17302060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ineffective treatment)
Study: 15818102
Drug: Omeprazole suspension
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole suspension
Study: 24473536
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (150-μg testosterone patch)
Study: 31033909
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (L. reuteri)
Study: 27684290
Drug: Aripiprazole treatment
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole treatment
Study: 2576363
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg
Study: 10877493
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (5,000 IU retinyl palmitate and 30 mg beta-carotene daily, plus 200,000 IU retinyl palmitate at delivery)
Study: 14686231
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir
Study: 16769180
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg oral THC (30 mg three times a day)
Study: 22483675
Drug: Dose-limiting constraints
Normalized name: Constrained Metal (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-limiting constraints
Study: 30585832
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid prophylaxis (80 mg daily for 14 days)
Study: 11032056
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment
Study: 31085338
Drug: Standard cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cut-off value for abnormal FIT result (20 or more μg hemoglobin/g feces)
Study: 31085338
Drug: Lower cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower cut-off value for abnormal FIT result (10 or more μg hemoglobin/g feces)
Study: 26491284
Drug: Pulmonary rehabilitation
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary rehabilitation with 18 µg of tiotropium once daily
Study: 22470429
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/d
Study: 10647072
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (5 mg/kg fat-free mass)
Study: 8137114
Drug: mianserin (antidepressant)
DrugBank: Mianserin (DB06148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin (antidepressant)
Study: 2512256
Drug: Immediate ibuprofen
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediate ibuprofen (2400 mg/day)
Study: 1861487
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I exercise therapy
Study: 28724636
Drug: Ranibizumab therapy
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab therapy
Study: 17879083
Drug: Sclerosing polidocanol
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sclerosing polidocanol injections (Group A)
Study: 24283110
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg (n=94)
Study: 29236049
Drug: Vitamin D₃
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D₃ 200,000 IU followed by monthly 100,000 IU doses (n = 226)
Study: 26003640
Drug: Imipenem administered
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem administered every 6 hours
Study: 21594660
Drug: Inpatient pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient pain therapy for 3 weeks
Study: 2515822
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy
Study: 3553496
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug groups
Study: 30799269
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with LB 266 mg/20 mL admixed with bupivacaine HCl 0.5% 20 mL
Study: 10622383
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion therapy (40 mg/kg, maximum 2 g)
Study: 26687471
Drug: L-PRF+ group
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF+ group (n = 17)
Study: 10664331
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with oral antibiotics (group 2)
Study: 8858230
Drug: Oral insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral insertion of thin video endoscope
Study: 1623912
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (850 mg) with tolbutamide (500 mg)
Study: 26528636
Drug: Median values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median values of galectin‐3 (13.4ng/mL)
Study: 2007319
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg anhydrous theophylline administered as a two-stage infusion during 24 hours
Study: 3716914
Drug: Caffeine administration
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine administration
Study: 2141247
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (Heptavax-B)